The global veterinary auto-immune therapeutics market is projected to be appraised at US$ 71,720.6 million by 2033, up from US$ 42,815.7 million in 2023, advancing at a CAGR of 5.3% from 2023 to 2033.
The adoption of veterinary auto-immune therapeutics is on the surge as several new ways of treating autoimmune diseases in animals using various drugs and other therapies like surgeries and stem cell therapies are evolving worldwide.
The demand for these drugs also rises as used to reduce the symptoms associated with the specific autoimmune disease. Furthermore, auto-immune disease treatment is gaining more attention owing to an increased threat of zoonotic disease transfer among humans, in turn, positively impacting the veterinary auto-immune therapeutics market outlook.
Hence, the growing incidence of zoonotic disease transfer is changing business operations of the animal healthcare industry as emergency care.
| Attributes | Details |
|---|---|
| Veterinary Auto-immune Therapeutics Market Share (2022) | US$ 41,087.7 million |
| Veterinary Auto-immune Therapeutics Market Share (2023) | US$ 42,815.7 million |
| Veterinary Auto-immune Therapeutics Market Share (2033) | US$ 71,720.6 million |
| Veterinary Auto-immune Therapeutics Market Share (2023 to 2033) | 5.3% |
The veterinary auto-immune therapeutics market growth is fuelled by veterinary hospitals as they are offering a wide range of therapeutic services for companion animals. An increase in the prevalence of autoimmune illness and a rise in Research and Development efforts to provide the best possible treatments in tandem with a surge in the use of therapeutics for the condition are also anticipated to contribute to the market growth in coming years.
Moreover, the market is expanded by the rise in autoimmune disease incidence and early illness detection, and the recent introduction of cutting-edge therapies during the forecast period. A significant number of late-stage pipeline medications are also present, including tocilizumab, certolizumab, baricitinib, etanercept, secukinumab, elotuzumab, abatacept, PF-06438179, apremilast, golimumab, certolizumab, ustekinumab, tofacitinib, and others.
The increasing transfer of zoonotic diseases among immunosuppressed patients is a prime factor responsible for the rising awareness of the auto-immune disease among companion animals.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The high threat of HIV transfer from the animal source to a person with suppressed immunity, and the transfer of allergic components from companion animals to family members are also spiking the demand for veterinary auto-immune therapeutics.
The growing incidence of autoimmune diseases in livestock animals has decreased the quality of meat consumed especially in pharmaceutical manufacturing. Moreover, the focus on livestock health among African countries which are the main exporters of livestock is further surging the demand for autoimmune disease therapy.
However, limited therapy options for animals in developing countries and a lack of awareness are hindering the growth of the veterinary auto-immune therapeutics market.
Due to numerous government-sponsored programs that promote these diagnostic tests, North America held the largest market share in the world for the diagnosis of animal auto-immune diseases accounting for 37.2% in 2022. The increased demand for all healthcare improvements for animal welfare is a result of the region's increased meat consumption.
There is a huge knowledge of the effects and impacts of auto-immune disorders thanks to their prevalence, in turn expanding the veterinary auto-immune therapeutics market size.
Principal Consultant
Europe held 26.5% of the veterinary auto-immune therapeutics market share in 2022. The main factor driving rising utilization rates is the increased awareness of animal autoimmune diseases brought on by programs in research, support, advocacy, and education.
The European Commission is pursuing a number of initiatives to raise public knowledge of the factors that may contribute to the onset of animal auto-immune diseases, thereby spurring the adoption of such therapeutics.
A Med City biotech company received more than US$330,000 in federal money to explore gene therapy for dogs and possibly people in the future. The National Institutes of Health has given a US$337,443 Phase I Small Business Innovation Research grant to Life Engine Animal Health, or LEAH Labs, led by CEO and co-founder Dr. Wes Wierson.
With assistance from the Mayo Clinic, Wierson developed gene editing methods that are used by LEAH Labs. The Mayo Clinic granted a license to LEAH Labs for the study. Downtown Rochester is where LEAH Labs is headquartered.
In the second quarter of 2022, pilot tests for the start-up's first product, a CAR-T cell therapy for cancerous dogs, are anticipated to begin. The objective is to develop a treatment for canine B cell lymphoma malignancy. An estimated 300,000 canines every year succumb to that form of cancer, which is analogous to Non-lymphoma Hodgkin's in people.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Market players are employing various organic and inorganic strategies including mergers & acquisitions, partnerships, collaborations, etc. in order to consolidate their position in the veterinary auto-immune therapeutics market.
A few of the recent developments in the veterinary auto-immune therapeutics market are:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Germany, United Kingdom, Nordic, Russia, BENELUX, Poland, France, Spain, Italy, Czech Republic, Hungary, Rest of EMEAI, Brazil, Peru, Argentina, Mexico, South Africa, Northern Africa, GCC Countries, China, Japan, South Korea, India, ASEAN, Thailand, Malaysia, Indonesia, Australia, New Zealand, Others |
| Key Segments Covered | Therapy Type, Disease Indication, Animal Type, Distribution Channel, Region |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Trend Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The market is estimated to secure a valuation of US$ 42,815.7 million in 2023.
The market is estimated to expand at a CAGR of 5.3% between 2023 and 2033.
The top 3 market players are Aratana Therapeutics Inc., Pfizer Inc., and Vet-Stem Inc.
North America generated 37.2% revenue in 2022.
The market is likely to be valued at US$ 71,720.6 million in 2033.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033 5.3.1. Corticosteroids, Azathioprine 5.3.2. Cyclosporine 5.3.3. Mycophenolate 5.3.4. Leflunomide 5.3.5. Cyclophosphamide 5.3.6. Levothyroxine 5.3.7. Folic Acid 5.3.8. Hydroxychloroquine 5.3.9. Chloroquine 5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033 6.3.1. Hypothyroidism 6.3.2. Pemphigus Disease 6.3.3. Canine Lupus 6.3.4. Auto-Immune Hemolytic Anemia 6.3.5. Bullous Pemphigoid 6.3.6. Discoid Lupus Erythematosus (DLE) 6.3.7. Immune-related arthritis 6.3.8. Others 6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Animal Type, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Animal Type, 2023 to 2033 7.3.1. Companion Animal 7.3.2. Dogs 7.3.3. Cats 7.3.4. Horse 7.3.5. Live Stock Animal 7.3.6. Cattle 7.3.7. Swine 7.3.8. Poultry 7.3.9. Fish 7.3.10. Sheep 7.4. Y-o-Y Growth Trend Analysis By Animal Type, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Animal Type, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Veterinary Hospitals 8.3.2. Veterinary Clinics 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. South Asia and Pacific 9.3.6. East Asia 9.3.7. Middle East and Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Therapy Type 10.2.3. By Disease Indication 10.2.4. By Animal Type 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Therapy Type 10.3.3. By Disease Indication 10.3.4. By Animal Type 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Therapy Type 11.2.3. By Disease Indication 11.2.4. By Animal Type 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Therapy Type 11.3.3. By Disease Indication 11.3.4. By Animal Type 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. UK 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Western Europe 12.2.2. By Therapy Type 12.2.3. By Disease Indication 12.2.4. By Animal Type 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Therapy Type 12.3.3. By Disease Indication 12.3.4. By Animal Type 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Poland 13.2.1.2. Russia 13.2.1.3. Czech Republic 13.2.1.4. Romania 13.2.1.5. Rest of Eastern Europe 13.2.2. By Therapy Type 13.2.3. By Disease Indication 13.2.4. By Animal Type 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Therapy Type 13.3.3. By Disease Indication 13.3.4. By Animal Type 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Bangladesh 14.2.1.3. Australia 14.2.1.4. New Zealand 14.2.1.5. Rest of South Asia and Pacific 14.2.2. By Therapy Type 14.2.3. By Disease Indication 14.2.4. By Animal Type 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Therapy Type 14.3.3. By Disease Indication 14.3.4. By Animal Type 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Therapy Type 15.2.3. By Disease Indication 15.2.4. By Animal Type 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Therapy Type 15.3.3. By Disease Indication 15.3.4. By Animal Type 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Therapy Type 16.2.3. By Disease Indication 16.2.4. By Animal Type 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Therapy Type 16.3.3. By Disease Indication 16.3.4. By Animal Type 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Therapy Type 17.1.2.2. By Disease Indication 17.1.2.3. By Animal Type 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Therapy Type 17.2.2.2. By Disease Indication 17.2.2.3. By Animal Type 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Therapy Type 17.3.2.2. By Disease Indication 17.3.2.3. By Animal Type 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Therapy Type 17.4.2.2. By Disease Indication 17.4.2.3. By Animal Type 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Therapy Type 17.5.2.2. By Disease Indication 17.5.2.3. By Animal Type 17.5.2.4. By Distribution Channel 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Therapy Type 17.6.2.2. By Disease Indication 17.6.2.3. By Animal Type 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Therapy Type 17.7.2.2. By Disease Indication 17.7.2.3. By Animal Type 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Therapy Type 17.8.2.2. By Disease Indication 17.8.2.3. By Animal Type 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Therapy Type 17.9.2.2. By Disease Indication 17.9.2.3. By Animal Type 17.9.2.4. By Distribution Channel 17.10. Poland 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Therapy Type 17.10.2.2. By Disease Indication 17.10.2.3. By Animal Type 17.10.2.4. By Distribution Channel 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Therapy Type 17.11.2.2. By Disease Indication 17.11.2.3. By Animal Type 17.11.2.4. By Distribution Channel 17.12. Czech Republic 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Therapy Type 17.12.2.2. By Disease Indication 17.12.2.3. By Animal Type 17.12.2.4. By Distribution Channel 17.13. Romania 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Therapy Type 17.13.2.2. By Disease Indication 17.13.2.3. By Animal Type 17.13.2.4. By Distribution Channel 17.14. India 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Therapy Type 17.14.2.2. By Disease Indication 17.14.2.3. By Animal Type 17.14.2.4. By Distribution Channel 17.15. Bangladesh 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Therapy Type 17.15.2.2. By Disease Indication 17.15.2.3. By Animal Type 17.15.2.4. By Distribution Channel 17.16. Australia 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Therapy Type 17.16.2.2. By Disease Indication 17.16.2.3. By Animal Type 17.16.2.4. By Distribution Channel 17.17. New Zealand 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Therapy Type 17.17.2.2. By Disease Indication 17.17.2.3. By Animal Type 17.17.2.4. By Distribution Channel 17.18. China 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Therapy Type 17.18.2.2. By Disease Indication 17.18.2.3. By Animal Type 17.18.2.4. By Distribution Channel 17.19. Japan 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Therapy Type 17.19.2.2. By Disease Indication 17.19.2.3. By Animal Type 17.19.2.4. By Distribution Channel 17.20. South Korea 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Therapy Type 17.20.2.2. By Disease Indication 17.20.2.3. By Animal Type 17.20.2.4. By Distribution Channel 17.21. GCC Countries 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Therapy Type 17.21.2.2. By Disease Indication 17.21.2.3. By Animal Type 17.21.2.4. By Distribution Channel 17.22. South Africa 17.22.1. Pricing Analysis 17.22.2. Market Share Analysis, 2022 17.22.2.1. By Therapy Type 17.22.2.2. By Disease Indication 17.22.2.3. By Animal Type 17.22.2.4. By Distribution Channel 17.23. Israel 17.23.1. Pricing Analysis 17.23.2. Market Share Analysis, 2022 17.23.2.1. By Therapy Type 17.23.2.2. By Disease Indication 17.23.2.3. By Animal Type 17.23.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Therapy Type 18.3.3. By Disease Indication 18.3.4. By Animal Type 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Aratana Therapeutics Inc. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Pfizer Inc. 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Vet-Stem, Inc. 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Ambrx Inc. 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Taconic Biosciences, Inc. 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. JBS Value (US$ Million)ed 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Virbac 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Eli Lilly and Company 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Jaguar Animal Health Inc. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Novartis AG 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Veterinary Auto-Immune Therapeutics Market
